Fermer le menu


Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancer 


Lyon, France, June 6th, 2022 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, provides an update on its CD39 program: Innate Pharma announced that IPH5201, the CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, will advance into a Phase 2 clinical trial in lung cancer. 


Lire le communiqué de presse

Plus d'infos